The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report - PubMed (original) (raw)

The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report

Leon J Schurgers et al. Clin J Am Soc Nephrol. 2010 Apr.

Abstract

Background and objectives: Vitamin K-dependent matrix Gla protein (MGP) acts as a calcification inhibitor in vitro and in vivo. The present study was performed to (1) determine plasma levels of the inactive, dephosphorylated, uncarboxylated MGP (dp-ucMGP) in a cohort of patients at different stages of chronic kidney disease (CKD) and (2) evaluate the association between dp-ucMGP levels on one hand and aortic calcification and mortality on the other.

Design, setting, participants, & measurements: 107 patients (67 +/- 13 years; 60% male; 32% at CKD stages 2 to 3, 31% at stages 4 to 5, 37% at stage 5D) were assayed for dp-ucMGP and underwent multislice spiral computed tomography scans to quantify aortic calcification at baseline. They were prospectively monitored for mortality.

Results: Plasma dp-ucMGP levels augmented progressively with CKD stage, with a significant difference from CKD stage 4. CKD stage, hemoglobin, age, and coumarin use were independently associated with plasma dp-ucMGP levels. Furthermore, plasma dp-ucMGP and age were positively and independently associated with the aortic calcification score. During follow-up (802 +/- 311 days), 34 patients died (20 from cardiovascular events). In a crude analysis, [plasma dp-ucMGP] > 921 pM was associated with overall mortality; this association was lost after adjusting for both age and the calculated propensity score.

Conclusions: Plasma dp-ucMGP increased progressively in a CKD setting and was associated with the severity of aortic calcification. Plasma dp-ucMGP could thus be a surrogate marker for vascular calcification in CKD.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Plasma dp-ucMGP levels by CKD stage. *P < 0.001 versus CKD stages 2 and 3. The dotted lines indicate the upper and lower boundaries of the plasma dp-ucMGP range in age-matched controls.

Figure 2.

Figure 2.

Exponential relationship between plasma dp-ucMGP levels and the estimated GFR, for patients at CKD stages 2 to 5 (n = 67), _r_2 = 0.268, P < 0.0001.

Figure 3.

Figure 3.

Linear relationship between aortic calcification score and plasma dp-ucMGP levels (n = 101), _r_2 = 0.143, P < 0.0001.

Figure 4.

Figure 4.

Kaplan-Meier estimates of overall mortality as a function of the median plasma dp-ucMGP level.

Similar articles

Cited by

References

    1. Parfrey PS, Foley RN: The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 10: 1606–1615, 1999 - PubMed
    1. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731–1740, 2003 - PubMed
    1. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M: Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 16: 978–983, 1996 - PubMed
    1. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218–223, 2000 - PubMed
    1. Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R., 3rd Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 66: 790–796, 1979 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources